Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Operating Leases (2019 - 2025)

Historic Operating Leases for Astrazeneca (AZNCF) over the last 10 years, with Q4 2025 value amounting to -$1.4 billion.

  • Astrazeneca's Operating Leases fell 2767.3% to -$1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.4 billion, marking a year-over-year decrease of 2767.3%. This contributed to the annual value of -$1.4 billion for FY2025, which is 2767.3% down from last year.
  • As of Q4 2025, Astrazeneca's Operating Leases stood at -$1.4 billion, which was down 2767.3% from -$1.4 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Operating Leases peaked at $1.1 billion during Q4 2023, and registered a low of -$1.4 billion during Q4 2025.
  • Moreover, its 5-year median value for Operating Leases was -$731.5 million (2021), whereas its average is -$614.5 million.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 36313.7% in 2021, then plummeted by 19867.02% in 2024.
  • Quarter analysis of 5 years shows Astrazeneca's Operating Leases stood at $987.0 million in 2021, then decreased by 3.44% to $953.0 million in 2022, then grew by 18.36% to $1.1 billion in 2023, then plummeted by 198.67% to -$1.1 billion in 2024, then dropped by 27.67% to -$1.4 billion in 2025.
  • Its last three reported values are -$1.4 billion in Q4 2025, -$1.4 billion for Q3 2025, and -$1.3 billion during Q2 2025.